Oral Poliovirus Vaccine Evolution and Insights Relevant to Modeling the Risks of Circulating Vaccine‐Derived Polioviruses (cVDPVs)
暂无分享,去创建一个
M. Pallansch | K. Thompson | R. D. Duintjer Tebbens | S. Cochi | O. Kew | O. Diop | C. Burns | M. Oberste | Jong-Hoon Kim | S. Wassilak
[1] R. Sutter,et al. Vaccine-derived polioviruses. , 2014, The Journal of infectious diseases.
[2] R. D. Tebbens,et al. Modeling Population Immunity to Support Efforts to End the Transmission of Live Polioviruses , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[3] M. Pallansch,et al. Expert Review on Poliovirus Immunity and Transmission , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[4] M. Pallansch,et al. Characterizing Poliovirus Transmission and Evolution: Insights from Modeling Experiences with Wild and Vaccine‐Related Polioviruses , 2013, Risk analysis : an official publication of the Society for Risk Analysis.
[5] F. Delpeyroux,et al. Common and diverse features of cocirculating type 2 and 3 recombinant vaccine-derived polioviruses isolated from patients with poliomyelitis and healthy children. , 2012, The Journal of infectious diseases.
[6] O. Kew. Reaching the last one per cent: progress and challenges in global polio eradication. , 2012, Current opinion in virology.
[7] Yong Zhang,et al. [Analysis of genetic characteristics of type II non-wild poliovirus in mainland China, 2010]. , 2012, Bing du xue bao = Chinese journal of virology.
[8] Z. Molnár,et al. Paralytic poliomyelitis associated with Sabin monovalent and bivalent oral polio vaccines in Hungary. , 2011, American journal of epidemiology.
[9] F. Delpeyroux,et al. Recombination between Poliovirus and Coxsackie A Viruses of Species C: A Model of Viral Genetic Plasticity and Emergence , 2011, Viruses.
[10] M. Pate,et al. Outbreak of Type 2 Vaccine-Derived Poliovirus in Nigeria: Emergence and Widespread Circulation in an Underimmunized Population , 2011, The Journal of infectious diseases.
[11] Wenbo Xu,et al. Type 2 vaccine-derived poliovirus from patients with acute flaccid paralysis in china: current immunization strategy effectively prevented its sustained transmission. , 2010, The Journal of infectious diseases.
[12] N. Nathanson,et al. From Emergence to Eradication: The Epidemiology of Poliomyelitis Deconstructed , 2010, American journal of epidemiology.
[13] W. Liu,et al. Emergence and Localized Circulation of a Vaccine-Derived Poliovirus in an Isolated Mountain Community in Guangxi, China , 2010, Journal of Clinical Microbiology.
[14] Z. Molnár,et al. Molecular characterization of poliovirus isolates from children who contracted vaccine-associated paralytic poliomyelitis (VAPP) following administration of monovalent type 3 oral poliovirus vaccine in the 1960s in Hungary. , 2010, FEMS immunology and medical microbiology.
[15] J. van de Kassteele,et al. Shedding of Vaccine Viruses with Increased Antigenic and Genetic Divergence after Vaccination of Newborns with Monovalent Type 1 Oral Poliovirus Vaccine , 2009, Journal of Virology.
[16] P. Minor. Vaccine-derived poliovirus (VDPV): Impact on poliomyelitis eradication. , 2009, Vaccine.
[17] Claire Blanchard,et al. Recombination between Polioviruses and Co-Circulating Coxsackie A Viruses: Role in the Emergence of Pathogenic Vaccine-Derived Polioviruses , 2009, PLoS pathogens.
[18] J. P. Davis,et al. Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. , 2009, The Journal of infectious diseases.
[19] P. Fine,et al. Estimating the Extent of Vaccine-Derived Poliovirus Infection , 2008, PloS one.
[20] Kimberly M Thompson,et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. , 2008, American journal of public health.
[21] M. Birmingham,et al. Reemergence of recombinant vaccine-derived poliovirus outbreak in Madagascar. , 2008, The Journal of infectious diseases.
[22] O. Kew,et al. Calibration of Multiple Poliovirus Molecular Clocks Covering an Extended Evolutionary Range , 2008, Journal of Virology.
[23] M. Pallansch,et al. A large vaccine-derived poliovirus outbreak on Madura Island--Indonesia, 2005. , 2008, The Journal of infectious diseases.
[24] R. Sutter,et al. Poliovirus vaccine-live , 2008 .
[25] D. Earn,et al. Circulating Vaccine Derived Polio Viruses and their Impact on Global Polio Eradication , 2008, Bulletin of mathematical biology.
[26] Kimberly M Thompson,et al. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. , 2008, Medscape journal of medicine.
[27] E. Wimmer,et al. Vaccination against polio should not be stopped , 2007, Nature Reviews Microbiology.
[28] Javier Martin,et al. Co-Circulation and Evolution of Polioviruses and Species C Enteroviruses in a District of Madagascar , 2007, PLoS pathogens.
[29] M. Pallansch,et al. Isolation of recombinant type 2 vaccine-derived poliovirus (VDPV) from a Nigerian child. , 2007, Virus research.
[30] S. Guillot,et al. Circulation of a type 1 recombinant vaccine-derived poliovirus strain in a limited area in Romania , 2007, Archives of Virology.
[31] Kimberly M Thompson,et al. Risks of Paralytic Disease Due to Wild or Vaccine‐Derived Poliovirus After Eradication , 2006, Risk analysis : an official publication of the Society for Risk Analysis.
[32] Wenbo Xu,et al. An outbreak of poliomyelitis caused by type 1 vaccine-derived poliovirus in China. , 2006, The Journal of infectious diseases.
[33] V. Agol. Vaccine-derived polioviruses. , 2006, Biologicals : journal of the International Association of Biological Standardization.
[34] M. Rennels,et al. Analysis of reversions in the 5'-untranslated region of attenuated poliovirus after sequential administration of inactivated and oral poliovirus vaccines. , 2006, The Journal of infectious diseases.
[35] Julie K. Pfeiffer,et al. Bottleneck-mediated quasispecies restriction during spread of an RNA virus from inoculation site to brain. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[36] M. Vignuzzi,et al. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population , 2006, Nature.
[37] Update on vaccine-derived polioviruses. , 2006, MMWR. Morbidity and mortality weekly report.
[38] V. Agol. Molecular mechanisms of poliovirus variation and evolution. , 2006, Current topics in microbiology and immunology.
[39] Pei-Jer Chen,et al. Intratypic Recombination among Lineages of Type 1 Vaccine-Derived Poliovirus Emerging during Chronic Infection of an Immunodeficient Patient , 2005, Journal of Virology.
[40] M. Pallansch,et al. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. , 2005, Annual review of microbiology.
[41] Kimberly M Thompson,et al. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. , 2005, American journal of epidemiology.
[42] E. Wimmer,et al. Poliovirus and poliomyelitis: a tale of guts, brains, and an accidental event. , 2005, Virus research.
[43] G. Dunn,et al. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains , 2005, Journal of medical virology.
[44] T. Nomura,et al. Genetic basis of the neurovirulence of type 1 polioviruses isolated from vaccine-associated paralytic patients , 2005, Archives of Virology.
[45] W. Hall,et al. Long-Term Excretion of Vaccine-Derived Poliovirus by a Healthy Child , 2004, Journal of Virology.
[46] Lilly Yuen,et al. Circulation of Type 1 Vaccine-Derived Poliovirus in the Philippines in 2001 , 2004, Journal of Virology.
[47] M. Pallansch,et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. , 2004, JAMA.
[48] Global Polio Eradication Initiative, strategic plan 2004-2008. , 2004, Releve epidemiologique hebdomadaire.
[49] Laboratory surveillance for wild and vaccine-derived polioviruses, January 2003-June 2004. , 2004, MMWR. Morbidity and mortality weekly report.
[50] Francis Delpeyroux,et al. Circulating vaccine-derived polioviruses: current state of knowledge. , 2004, Bulletin of the World Health Organization.
[51] V. Agol,et al. Retrospective Analysis of a Local Cessation of Vaccination against Poliomyelitis: a Possible Scenario for the Future , 2003, Journal of Virology.
[52] M. Pallansch,et al. Serial Recombination during Circulation of Type 1 Wild-Vaccine Recombinant Polioviruses in China , 2003, Journal of Virology.
[53] M. Pallansch,et al. Circulation of Endemic Type 2 Vaccine-Derived Poliovirus in Egypt from 1983 to 1993 , 2003, Journal of Virology.
[54] D. Rousset,et al. Recombinant Vaccine–Derived Poliovirus in Madagascar , 2003, Emerging infectious diseases.
[55] A. Plebani,et al. Nucleotide variation in Sabin type 2 poliovirus from an immunodeficient patient with poliomyelitis. , 2003, The Journal of general virology.
[56] M. L. Yakovenko,et al. Long-Term Circulation of Vaccine-Derived Poliovirus That Causes Paralytic Disease , 2002, Journal of Virology.
[57] T. Kitamura,et al. Prevalence of vaccine-derived polioviruses in the environment. , 2002, The Journal of general virology.
[58] M. Pallansch,et al. Outbreak of Poliomyelitis in Hispaniola Associated with Circulating Type 1 Vaccine-Derived Poliovirus , 2002, Science.
[59] R. Sutter,et al. Vaccine-associated paralytic poliomyelitis in India during 1999: decreased risk despite massive use of oral polio vaccine , 2002 .
[60] R. Sutter,et al. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[61] S. Guillot,et al. Genomic Features of Intertypic Recombinant Sabin Poliovirus Strains Excreted by Primary Vaccinees , 2001, Journal of Virology.
[62] Transmission of wild poliovirus type 2--apparent global interruption. , 2001, Releve epidemiologique hebdomadaire.
[63] Javier Martin,et al. The vaccine origin of the 1968 epidemic of type 3 poliomyelitis in Poland. , 2000, Virology.
[64] T. Kitamura,et al. Assessment of Poliovirus Eradication in Japan: Genomic Analysis of Polioviruses Isolated from River Water and Sewage in Toyama Prefecture , 2000, Applied and Environmental Microbiology.
[65] S. Guillot,et al. Natural Genetic Exchanges between Vaccine and Wild Poliovirus Strains in Humans , 2000, Journal of Virology.
[66] V. Agol,et al. Evolution of Circulating Wild Poliovirus and of Vaccine-Derived Poliovirus in an Immunodeficient Patient: a Unifying Model , 2000, Journal of Virology.
[67] Javier Martin,et al. Evolution of the Sabin Strain of Type 3 Poliovirus in an Immunodeficient Patient during the Entire 637-Day Period of Virus Excretion , 2000, Journal of Virology.
[68] A. Heim,et al. Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. , 1999, Virology.
[69] P E Fine,et al. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. , 1999, American journal of epidemiology.
[70] P. McIntyre,et al. Vaccine-associated paralytic poliomyelitis. , 1999, Communicable diseases intelligence.
[71] Progress towards global poliomyelitis eradication. The approaching extinction of wild poliovirus type 2. , 1999, Releve epidemiologique hebdomadaire.
[72] M. Pallansch,et al. Prolonged Replication of a Type 1 Vaccine-Derived Poliovirus in an Immunodeficient Patient , 1998, Journal of Clinical Microbiology.
[73] M. Georgescu,et al. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis , 1997, Journal of virology.
[74] R. Linkins,et al. Sequential use of inactivated poliovirus vaccine followed by oral poliovirus vaccine in Oman. , 1997, The Journal of infectious diseases.
[75] X. L. Zhang,et al. Surveillance for polio eradication in the People's Republic of China. , 1997, The Journal of infectious diseases.
[76] M. Pallansch,et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. , 1996, JAMA.
[77] S. Elena,et al. Basic concepts in RNA virus evolution , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[78] K. Chumakov,et al. Limited genetic changes in the Sabin 1 strain of poliovirus occurring in the central nervous system of monkeys. , 1996, The Journal of general virology.
[79] H. Schatzmayr,et al. Poliovirus type 1 isolated from a vaccine-associated case of paralytic poliomyelitis in Brazil. , 1996, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[80] J. Meredith,et al. Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus , 1995, Journal of virology.
[81] M. Georgescu,et al. Tripartite genome organization of a natural type 2 vaccine/nonvaccine recombinant poliovirus. , 1995, The Journal of general virology.
[82] M. Bouchard,et al. Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine , 1995, Journal of virology.
[83] H. Schatzmayr,et al. Genomic characterization of type 1 Sabin-related polioviruses isolated in Brazil. , 1995, Acta virologica.
[84] J. Modlin,et al. Vaccine-Associated Paralytic Poliomyelitis , 1994, Journal of child neurology.
[85] Z. Lu,et al. Microevolution of Sabin 1 strain in vitro and genetic stability of oral poliovirus vaccine. , 1994, Virology.
[86] S. Guillot,et al. Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction. , 1994, Vaccine.
[87] S. Koike,et al. Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence , 1994, Journal of virology.
[88] J. Andrus,et al. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies. , 1994, Bulletin of the World Health Organization.
[89] M. Furione,et al. Polioviruses with natural recombinant genomes isolated from vaccine-associated paralytic poliomyelitis. , 1993, Virology.
[90] F. Tekaia,et al. A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice , 1993, Journal of virology.
[91] M. Furione,et al. Genomic modifications in naturally occurring neurovirulent revertants of Sabin 1 polioviruses. , 1993, Developments in biological standardization.
[92] S. R. Pollard,et al. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. , 1993, Virology.
[93] P. Minor. The molecular biology of poliovaccines. , 1992, The Journal of general virology.
[94] G. Schild,et al. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating , 1992, Journal of virology.
[95] K. Dimock,et al. Genetic characterization of Sabin types 1 and 3 poliovaccine virus following serial passage in the human intestinal tract. , 1992, Biologicals : journal of the International Association of Biological Standardization.
[96] M. Pallansch,et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[97] V. Agol,et al. Frequent isolation of intertypic poliovirus recombinants with serotype 2 specificity from vaccine‐associated polio cases , 1991, Journal of medical virology.
[98] C. Weeks-Levy,et al. Identification and characterization of a new base substitution in the vaccine strain of Sabin 3 poliovirus. , 1991, Virology.
[99] V. Agol,et al. Coupled mutations in the 5'-untranslated region of the Sabin poliovirus strains during in vivo passages: structural and functional implications. , 1991, Virus research.
[100] L. M. Onotato. MUCOSAL IMMUNITY INDUCED BY ENHANCED POTENCY INACTIVATED AND ORAL POLIO VACCINES , 1991 .
[101] L. Fiore,et al. Identification of a consistent pattern of mutations in neurovirulent variants derived from the sabin vaccine strain of poliovirus type 2 , 1991, Journal of virology.
[102] S. R. Pollard,et al. The 5' noncoding region of the type 2 poliovirus vaccine strain contains determinants of attenuation and temperature sensitivity. , 1991, Virology.
[103] R. Ren,et al. Identification of two determinants that attenuate vaccine-related type 2 poliovirus , 1991, Journal of virology.
[104] C. Wychowski,et al. Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model. , 1991, Virology.
[105] I. Onorato,et al. Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. , 1991, The Journal of infectious diseases.
[106] G. Dunn,et al. Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources , 1990, Journal of medical virology.
[107] C. Christodoulou,et al. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature , 1990, Journal of virology.
[108] S. R. Pollard,et al. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine , 1989, Journal of virology.
[109] J. Almond,et al. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. , 1989, Virology.
[110] A. Nomoto,et al. Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype , 1989, Journal of virology.
[111] G. Schild,et al. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine , 1989, Journal of virology.
[112] G. Dunn,et al. The effect of sequences in the 5' non-coding region on the replication of polioviruses in the human gut. , 1988, The Journal of general virology.
[113] L. Schonberger,et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. , 1987, JAMA.
[114] A. Kameda,et al. Genetic analysis of the attenuation phenotype of poliovirus type 1 , 1986, Journal of virology.
[115] J. Icenogle,et al. Antigenic and molecular evolution of the vaccine strain of type 3 poliovirus during the period of excretion by a primary vaccinee. , 1986, The Journal of general virology.
[116] J. Maizel,et al. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome , 1985, Nature.
[117] M. Mulders,et al. Molecular epidemiology of polioviruses. , 1995, Reviews of infectious diseases.
[118] A. Cann,et al. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. , 1984, Nucleic acids research.
[119] R. Bernier. Some observations on poliomyelitis lameness surveys. , 1984, Reviews of infectious diseases.
[120] I. Dömök. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982. , 1984, Reviews of infectious diseases.
[121] R. Mountford,et al. Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[122] S. Kuge,et al. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[123] The relation between acute persisting spinal paralysis and poliomyelitis vaccine--results of a ten-year enquiry. WHO Consultative Group. , 1982, Bulletin of the World Health Organization.
[124] O. Kew,et al. Multiple genetic changes can occur in the oral poliovaccines upon replication in humans. , 1981, The Journal of general virology.
[125] A. Kulesza,et al. The epidemic of type 3 poliomyelitis in Poland in 1968. , 1970 .
[126] J. Melnick,et al. Studies of the immunogenicity, communicability and genetic stability of oral poliovaccine administered during the winter. , 1967, American journal of epidemiology.
[127] A. Beale,et al. A study of polio vaccination in infancy: excretion following challenge with live virus by children given killed or living poliovaccine , 1966, Journal of Hygiene.
[128] V. Pavilanis,et al. A STUDY OF SABIN TYPE 1 ORAL VACCINE VIRUS DURING FIVE HUMAN PASSAGES. , 1964, Revue canadienne de biologie.
[129] G. Dick,et al. Vaccination Against Poliomyelitis with Live Virus Vaccines—6* , 1961, British medical journal.
[130] Y. Ghendon,et al. Comparison of the Resistance of the Intestinal Tract to Poliomyelitis virus (Sabin's Strains) in Persons after Naturally and Experimentally Acquired Immunity. , 1961 .
[131] E. Ludwig,et al. Possible protective effect of previous type 2 infection against paralytic poliomyelitis due to type 1 virus. , 1957, American journal of hygiene.
[132] J. Salk. REQUIREMENTS FOR PERSISTENT IMMUNITY TO POLIOMYELITIS , 1956, Transactions of the Association of American Physicians.
[133] A. Shelokov,et al. RELATION OF POLIOMYELITIS VIRUS TYPES TO CLINICAL DISEASE AND GEOGRAPHIC DISTRIBUTION: A PRELIMINARY REPORT , 1955, Annals of the New York Academy of Sciences.
[134] L. Reed,et al. A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .